In the longest prospective clinical trial ever conducted in the treatment of postmenopausal osteoporosis -- a chronic condition that can lead to bone loss and susceptibility to fractures -- researchers found that postmenopausal women taking FOSAMAX(R) (alendronate sodium) maintained or continued to experience increases in bone mineral density (BMD) at the hip and spine through 10 years of treatment. Results from the trial were published today in the New England Journal of Medicine. FOSAMAX is the only medicine approved by the Food and Drug Administration in the treatment of osteoporosis to increase BMD and reduce the incidence of both spine and hip fractures in postmenopausal women.